C1q, antibodies and anti-C1q autoantibodies

Beurskens, Frank J.; Schaarenburg, Rosanne A. van; Trouw, Leendert A.

doi:10.1016/j.molimm.2015.05.010

Cited by 60 publications

(48 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the generation of autoantibodies (reviewed in (Beurskens et al, 2015)) and IC deposition leading to chronic inflammation and tissue/organ destruction. C1q–deficiency in humans results in development of SLE or an SLE-like syndrome (Manderson et al, 2004; Stegert et al, 2015) consistent with a role for C1q in clearance of IC.…”

Section: Classical Functions: Complement Phagocytosis and Cytokinmentioning

confidence: 99%

C1q: A fresh look upon an old molecule

Thielens

Tedesco

Bohlson

et al. 2017

Molecular Immunology

181

139

View full text Add to dashboard Cite

Originally discovered as part of C1, the initiation component of the classical complement pathway, it is now appreciated that C1q regulates a variety of cellular processes independent of complement activation. C1q is a complex glycoprotein assembled from 18 polypeptide chains, with a C-terminal globular head region that mediates recognition of diverse molecular structures, and an N-terminal collagen-like tail that mediates immune effector mechanisms. C1q mediates a variety of immunoregulatory functions considered important in the prevention of autoimmunity such as the enhancement of phagocytosis, regulation of cytokine production by antigen presenting cells, and subsequent alteration in T-lymphocyte maturation. Furthermore, recent advances indicate additional roles for C1q in diverse physiologic and pathologic processes including pregnancy, tissue repair, and cancer. Finally, C1q is emerging as a critical component of neuronal network refinement and homeostatic regulation within the central nervous system. This review summarizes the classical functions of C1q and reviews novel discoveries within the field.

show abstract

Section: Classical Functions: Complement Phagocytosis and Cytokinmentioning

confidence: 99%

C1q: A fresh look upon an old molecule

Thielens

Tedesco

Bohlson

et al. 2017

Molecular Immunology

181

139

View full text Add to dashboard Cite

show abstract

“…Until now, only TPOAb serve as a predictor of postpartum thyroiditis (PPT), apart from thyroid ultrasound [7]. Complement-activating TPOAb were found to be increased Anti-C1q antibodies in pregnancy V C 2016 British Society for Immunology, Clinical and Experimental Immunology, 186: [10][11][12][13][14][15][16][17] in women with PPT [31,32]. However, only approximately half the TPOAb-positive women developed PPT after delivery, and the mechanisms that might be involved remain unclear.…”

Section: Discussionmentioning

confidence: 99%

Anti-C1q autoantibodies are linked to autoimmune thyroid disorders in pregnant women

Vítková

Jiskra

Springer

et al. 2016

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Anti-C1q antibodies (anti-C1q) have been implicated in the pathogenesis of autoimmune diseases, including autoimmune thyroid disorders (AITD). The aim of this study was to evaluate the association between anti-C1q and thyroid function in pregnancy-associated AITD. In 96 pregnant women screened positive for AITD (thyroid dysfunction and/or antibodies against thyroperoxidase - TPOAb), anti-C1q were measured during the 9-11th gestational week and after delivery (median 16 months after delivery), and compared to the corresponding serum levels of thyroid hormones. As controls, 80 healthy pregnant women, 72 non-pregnant AITD patients and 72 blood donors were included. In the non-pregnant AITD group, two serum samples ≥ 6 months apart were analysed. Compared to blood donors, anti-C1q levels were substantially higher in all pregnant women analysed. In pregnancy, anti-C1q levels were higher in the TPOAb-positive women than in controls (37 versus 17·5%, P < 0·0001). Anti-C1q-positive pregnant women screened positive for AITD had higher thyroid-stimulating hormone (TSH) levels than anti-C1q-negative women (2·41 versus 1·94 mU/l, P = 0·01), and TSH correlated positively with anti-C1q (r = 0·226, P = 0·045) in the TPOAb-positive women. After delivery, serum levels of anti-C1q decreased in the positively screened TPOAb-negative women (8·8 versus 5·9 U/l, P = 0·002), but not in the TPOAb-positive ones, and they no longer correlated with TSH. Anti-C1q antibody levels increase during pregnancy in general and even more in the context of AITD, where they correlate with thyroid stimulating hormone levels.

show abstract

“…The patient did have positive anti-C1q IgG antibodies. C1q antibodies are present in 2–8% of the healthy population but are present in 30–48% of SLE patients [17, 19]. C1q antibodies are associated with intense activation of the classical complement pathway resulting in low levels of C1q, C4, and C2 [17, 20].…”

Section: Discussionmentioning

confidence: 99%

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?

Raj

Waters

2016

Case Reports in Rheumatology

View full text Add to dashboard Cite

Activation of the classical pathway complement system has long been implicated in stimulating immune complex mediated tissue destruction in systemic lupus erythematosus (SLE). C3 and C4 complement levels are utilized as part of SLE diagnosis and monitoring criteria. Recently, cell bound complement activation products (CBCAPs) have shown increased sensitivity in diagnosing and monitoring lupus activity, compared to traditional markers. CBCAPs are increasingly utilized in rheumatology practice as additional serological markers in evaluating SLE patients. We report a case of a patient diagnosed with SLE that had chronically low C3 and C4, along with negative CBCAPs. We surmise that the patient has an inherited complement deficiency as the etiology of her SLE and that CBCAPs could be used to predict such deficiency.

show abstract

C1q, antibodies and anti-C1q autoantibodies

Cited by 60 publications

References 126 publications

C1q: A fresh look upon an old molecule

C1q: A fresh look upon an old molecule

Anti-C1q autoantibodies are linked to autoimmune thyroid disorders in pregnant women

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?

Contact Info

Product

Resources

About